Towards best-practice access to services for culturally and linguistically diverse people with a disability

The research set out to understand the characteristics of good practice to increase access to systems and services for people with disability from culturally and linguistically diverse communities. The report finds many governments, businesses, not-for profit organisations and community organisations have policies or programs that support the inclusion of people with disability and people from culturally and linguistically diverse backgrounds. However, these policies or programs are often not integrated with each other or with other initiatives. It finds the policies or programs are often not properly implemented or adequately monitored or evaluated. In order for services to be accessible for people with disability from culturally and linguistically diverse backgrounds the report identifies ‘good practice’ should occur at three levels: - systemic level – for example, the Australian Government should provide information in different languages - organisational level – for example, organisations should have people with disability from culturally and linguistically diverse backgrounds on boards and employ people from diverse backgrounds. - individual level – for example, staff working to service these people’s needs should learn how to work with interpreters and with people from different backgrounds. ‘Good practice’ in the provision of services involves three key elements: - an understanding of and engagement with intersecting experiences of people with disability from culturally and linguistically diverse backgrounds. - involvement of people with disability from culturally and linguistically diverse backgrounds at all stages of developing, implementing and managing services. - continuous monitoring and improvement to adjust systems so they can respond to the needs of people with disability from culturally and linguistically diverse backgrounds. An organisational commitment to implementing good practice across systems and services has the potential to increase access to services and ensure the safety of people with disability from culturally and linguistically diverse backgrounds

Legislative Documents

Also, variously referred to as: House bills; House documents; House legislative documents; legislative documents; General Court documents

Effect of adiposity on tissue-specific adiponectin secretion - Fig 3

<p>A: Secretion levels of adiponectin from visceral adipose tissue (VAT) is negatively associated with BMI while there was no association with subcutaneous adipose tissue (SAT) (p < 0.05) B: Secretion levels of adiponectin from VAT is negatively associated with total fat mass while there was no association with SAT (p < 0.001) C: Secretion levels of adiponectin from VAT is negatively associated with visceral fat percentage while there was no association with SAT (p < 0.05).</p

Baseline demographic, anthropometric, and metabolic characteristics (mean ± SD).

<p>Baseline demographic, anthropometric, and metabolic characteristics (mean ± SD).</p

Visceral adipose tissue (VAT) (A) and subcutaneous adipose tissue (SAT) (B) tissue homogenates (50 μg protein) were separated by 15% SDS-PAGE and transferred to nitrocellulose membranes for immunoblot analyses.

<p>Adiponectin (ADPN) levels from paired SAT and VAT samples are shown for 7 different subjects. Beta-actin loading control and monomeric recombinant adiponectin (~30 kDa) are shown).</p

Associations of adiposity measures with tissue specific adiponectin secretion.

<p>Associations of adiposity measures with tissue specific adiponectin secretion.</p

Correlations of BMI with metabolic characteristics.

<p>Correlations of BMI with metabolic characteristics.</p

Secretion levels of adiponectin from both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) at 4 hours and 24 hours were highly correlated with each other (p < 0.001).

<p>Secretion levels of adiponectin from both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) at 4 hours and 24 hours were highly correlated with each other (p < 0.001).</p

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (vcu-art2) pilot study]

A first pilot study of interleukin-1 blockade in ST-segment elevation acute myocardial infarction showed improved remodeling. In the present second pilot study, we enrolled 30 patients with clinically stable ST-segment elevation acute myocardial infarction randomized to anakinra, recombinant interleukin-1 receptor antagonist, 100 mg/day for 14 days or placebo in a double-blind fashion. The primary end point was the difference in the interval change in left ventricular (LV) end-systolic volume index between the 2 groups within 10 to 14 weeks. The secondary end points included changes in the LV end-diastolic volume index, LV ejection fraction, and C-reactive protein levels. No significant changes in end-systolic volume index, LV end-diastolic volume index, or LV ejection fraction were seen in the placebo group. Compared to placebo, treatment with anakinra led to no measurable differences in these parameters. Anakinra significantly blunted the increase in C-reactive protein between admission and 72 hours (+0.8 mg/dl, interquartile range -6.4 to +4.2, vs +21.1 mg/dl, interquartile range +8.7 to +36.6, p = 0.002), which correlated with the changes in LV end-diastolic volume index and LV end-systolic volume index at 10 to 14 weeks (R = +0.83, p = 0.002, and R = +0.55, p = 0.077, respectively). One patient in the placebo group (7%) died. One patient (7%) in the anakinra group developed recurrent acute myocardial infarction. More patients were diagnosed with new-onset heart failure in the placebo group (4, 27%) than in the anakinra group (1, 7%; p = 0.13). When the data were pooled with those from the first Virginia Commonwealth University-Anakinra Remodeling Trial (n = 40), this difference reached statistical significance (30% vs 5%, p = 0.035). In conclusion, interleukin-1 blockade with anakinra blunted the acute inflammatory response associated with ST-segment elevation acute myocardial infarction. Although it failed to show a statistically significant effect on LV end-systolic volume index, LV end-diastolic volume index, or LV ejection fraction in this cohort of clinically stable patients with near-normal LV dimensions and function, anakinra led to a numerically lower incidence of heart failure. © 2013 Elsevier Inc. All rights reserved